MedPath

Inhalation of Low Molecular Weight Heparins as a prophylaxis to prevent SARS-CoV-2 infectio

Completed
Conditions
corona virus infection
COVID-19
10047438
Registration Number
NL-OMON50776
Lead Sponsor
Academisch Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
28
Inclusion Criteria

Healthy men and women between ages 18-65 with no medical history of
immunodeficiencies or chronic illness.

Exclusion Criteria

COVID-19 in the volunteers medical history.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Primary endpoint: SARS-CoV-2 binding to the isolated cells will be measured by<br /><br>the SARS-CoV-2 binding assay to obtain a proof of concept that in vivo<br /><br>application of LMWH block virus binding. The amount of total virus bound to<br /><br>epithelial cells will be measured in pg/ml. </p><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath